| Product Code: ETC8315258 | Publication Date: Sep 2024 | Updated Date: Oct 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Overview |
3.1 Monaco Country Macro Economic Indicators |
3.2 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, 2021 & 2031F |
3.3 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market - Industry Life Cycle |
3.4 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market - Porter's Five Forces |
3.5 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
3.6 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By Gene Type, 2021 & 2031F |
3.7 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.8 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.9 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of alpha-1 antitrypsin deficiency (AATD) globally |
4.2.2 Rising awareness about AATD and available treatment options |
4.2.3 Technological advancements in augmentation therapy for AATD |
4.3 Market Restraints |
4.3.1 High cost associated with augmentation therapy for AATD |
4.3.2 Limited availability of approved therapies for AATD |
4.3.3 Stringent regulatory requirements for approval of AATD treatments |
5 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Trends |
6 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Types |
6.1 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Drugs |
6.1.1 Overview and Analysis |
6.1.2 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Drugs, 2021- 2031F |
6.1.3 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Prolastin, 2021- 2031F |
6.1.4 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Zemaira/Respreeza, 2021- 2031F |
6.1.5 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Glassia, 2021- 2031F |
6.1.6 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Aralast NP, 2021- 2031F |
6.1.7 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Gene Type |
6.2.1 Overview and Analysis |
6.2.2 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Type PiZZ, 2021- 2031F |
6.2.3 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Type PiMS, 2021- 2031F |
6.2.4 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Type PiMZ, 2021- 2031F |
6.2.5 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Application |
6.3.1 Overview and Analysis |
6.3.2 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Lung Disease, 2021- 2031F |
6.3.3 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Liver Disease, 2021- 2031F |
6.3.4 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Population Type, 2021- 2031F |
6.3.5 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Adults and Pediatric, 2021- 2031F |
6.4 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.4.4 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Home Healthcare, 2021- 2031F |
6.4.5 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.5.3 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.5.4 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.5.5 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Others, 2021- 2031F |
7 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Import-Export Trade Statistics |
7.1 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Export to Major Countries |
7.2 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Imports from Major Countries |
8 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Key Performance Indicators |
8.1 Patient adherence rate to augmentation therapy |
8.2 Number of clinical trials for new AATD therapies |
8.3 Rate of adoption of augmentation therapy in newly diagnosed AATD patients |
9 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market - Opportunity Assessment |
9.1 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By Drugs, 2021 & 2031F |
9.2 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By Gene Type, 2021 & 2031F |
9.3 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By Application, 2021 & 2031F |
9.4 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By End User, 2021 & 2031F |
9.5 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market - Competitive Landscape |
10.1 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue Share, By Companies, 2024 |
10.2 Monaco Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here